Johnson & Johnson is recalling products that contain a carcinogen

The New Jersey-based company said consumers should refrain from using and discarding these products, after tests detected low levels of benzene in some samples.

The company also notified distributors and retailers to stop selling these products and arrange for them to be returned “out of an abundance of caution.”

Benzene is classified as a carcinogen and may lead to cancer, depending on the level and extent of exposure.

Johnson & Johnson said benzene is not an ingredient in its sunscreen products, and it is investigating why products are contaminated with it.

“It is not expected that daily exposure to benzene in these sprays of sunscreen at the levels that we have observed in our tests will result in adverse health complications,” the company was quoted by Reuters as saying.

The company’s recalled products include Neutrogena Beach Defense, Neutrogena Coldry Sport, Neutrogena Invisible Daily Defense and Neutrogena Ultra SheroAveno Protect + Refresh.

.

Guillain-Barré syndrome is triggered by anti-Covid vaccines

The Guillain-Barré syndrome is the new adverse effect produced by some of the vaccines antiCovid, some of them are AstraZeneca-Oxford, Pfizer-BioNTech Y Johnson & Johnson. Although it has affected very few people, its manifestation is worrying, since it encourages the Facial paralysis, and if it gets complicated, it could trigger areflexic quadriplegia and the need for respiratory assistance.

Interest in this neurological disorder arose after the Food and Drug Administration (FDA), from the United States, will notify through Federal System for Notification of Adverse Events to Vaccines (VAERS, for its acronym in English), 95 provoked cases of this syndrome, which required hospitalization.

However, Guillain-Barré syndrome (GBS) had already been detected in seven vaccinated people, with the AstraZeneca vial, in India. This manifestation occurred in the first four weeks, after having received the first dose.

Read also: US alert for cases of Guillain-Barré syndrome linked to Johnson & Johnson vaccine

From there, different research groups have devoted themselves to delving into its appearance, because although this condition is very unusual, it is potentially serious and can cause death.

That is why experts suggested that it is a variant of the disease. This is consistent with the GBS description published by “ScienceDirect”, in which they state that it encompasses a number of different “recognizable variables.”

One of the efforts around this phenomenon was published in the “Wiley Online Library”. The scientists studied four of the seven cases, in which the affected patients were women who ranged from 43 to 68 years, (only one of the seven affected was male) in the Kerala Medical Center, on the costa Malabar india.

Read also: Myocarditis, the new adverse effect of the Pfizer and Moderna anti-Covid vaccines

Among the symptoms reported by the mourners, weakness in the limbs predominated, facial numbness and lingual, difficulty passing food -dysphagia-, as well as back pain.

As of the date the results were released, on June 10, 2021, the researchers said that of the seven GBS patients, six had not recovered and one had been discharged. All of them required mechanic ventilation to control the effects of the syndrome.

The experts concluded that this disease occurs very infrequently, registering 17 cases per one million inhabitants per year. But they urged the health authorities to pay attention and plan a way to address the events that may occur during the anti-Covid vaccination days, as their effects are serious.

“Overall, our experience should prompt all clinicians to be vigilant in recognizing GBS in vaccinated patients. While the risk per patient may be relatively low, our observations suggest that this clinically distinct GBS variant is more severe than usual and may require mechanical ventilation, “says the document.

Read also: Alcohol and Covid Vaccination: Expert Unravels What Happens If We Combine Them

What else is known about Guillain-Barré syndrome?

This disease is part of the conditions that attack the immune system. The GBS specifically attacks the nerve cells.

The neurons, as they are better known, establish connections with muscle cells Y glandulares for the proper functioning of the nervous system.

When a person has GBS they will experience symptoms for about two weeks. However, the disease can cause irreversible damage.

The causes have been associated as a secondary effect of a primary disease, this can be a Respiratory infection, such as seasonal flu, or gastrointestinal like salmonella. They usually present 7 to 15 days after the onset of the disease.

Read also: Covid-19: Lambda variant could be as transmissible as Delta and is already in 29 countries

According to the Centers for Disease Control and Prevention (CDC), this disease is more common in men over 50 years of age.

To date, scientific evidence has not proven about the genetic or social factors that cause a small number of patients to suffer from it.

The recovery of GBS can be favorable, if it is treated on time and with constant medical follow-up, that is why experts recommend that treatment begin immediately after being diagnosed.

mlc

.

Johnson & Johnson vaccine will need booster from Pfizer or Moderna

NEW YORK – Two weeks ago, virologist Angela Rasmussen received a dose of the Pfizer-BioNTech coronavirus vaccine to boost her immune system, which was already primed by a Johnson & Johnson vaccine.

No US health agency has recommended this combination of vaccines. And Rasmussen, a research scientist with the Organization for Vaccines and Infectious Diseases at the University of Saskatchewan in Canada, is confident in data showing that one dose of Johnson & Johnson will prevent her from being hospitalized with Covid-19.

But she was concerned about a rare infection after vaccination. The emergence of the delta variant, a version of the coronavirus that spreads more easily from person to person, worried Rasmussen. The Pfizer injection, he said, could strengthen its protection against that variant or help prevent it from spreading.

Rasmussen received one of 12 million doses of Johnson & Johnson’s vaccine administered so far in the United States. Meanwhile, as of mid-June, 130 million Moderna and 17.105 million Pfizer injections had been given to people in the United States, according to the Centers for Disease Control and Prevention. Numerous studies have shown that the Pfizer and Moderna vaccines, which belong to a class of vaccines that use molecules called mRNAs, are effective against delta and other variants. Fewer studies address Johnson & Johnson’s strength versus variants.

Because more scientific reports involve mRNA vaccines rather than Johnson & Johnson vaccines, Rasmussen said he believes that people who received the Johnson & Johnson vaccine “feel abandoned.” Some of those people may wonder if they need reinforcement too.

Is it necessary to combine the Johnson vaccine with another vaccine?

The Johnson & Johnson vaccine, like the other two vaccines licensed by the Food and Drug Administration, vigorously protects against serious illness, hospitalization and death.

“If you look at the people who are being hospitalized now, they are actually those who have not been vaccinated before,” said Robert Atmar, professor of infectious diseases at Baylor College of Medicine in Houston. “From a public health standpoint, what we have to do, in my opinion, is try to get our populations that are not vaccinated to accept a vaccine that is readily available and that will have a much greater impact.”

The need for booster injections largely depends on the efficacy of the three licensed vaccines against circulating variants, particularly the highly transmissible delta variant, and for how long a fully vaccinated person is protected.

Is it safe to boost the Johnson vaccine with a dose of mRNA?

Research on mixed booster doses is ongoing in the United States. The National Institutes of Health recently announced the initiation of a clinical trial that aims to assess the safety and immune responses to a mixed booster regimen. Atmar, one of the lead researchers, said the researchers hope to have data on how well the approach works later this summer or early fall. Security information would likely be available much sooner, he said.

.

Experts: This vaccine requires re-vaccination

The vaccination campaign is in full swing. But are all vaccines equally effective, especially against the more contagious Delta variant and possible new mutants? Virologists have great doubts about a vaccine.

The Delta-Variant hovers as a bad omen over autumn in Germany. Last but not least, it makes it clear that the more contagious variant that first appeared in India could not have been the last mutant to prevail. One vaccine, however, is of particular concern to the experts with regard to its protective effect: the active ingredient of Johnson & Johnson.

Johnson & Johnson: 36 million cans ordered

The vector vaccine has a unique selling point compared to the other preparations approved in Germany: It only needs to be vaccinated once. The federal government ordered more than 36 million cans by the end of the year.

First of all, it was vaccinated in places where it was difficult to reach people for a second vaccination, for example in the case of the homeless. The vaccination protection of the product was lower than that of all other preparations from the start. It is around 65 percent. Translated: the probability of Covid-19 to get sick is loud Robert Koch Institute 65 percent less than in unvaccinated people.

Johnson & Johnson’s effectiveness is controversial

All three other vaccines approved in Germany have significantly higher values ​​(between 80 and 95 percent). The protection against severe courses (hospitalization) is also 100 percent at J&J. Still: The relatively low effectiveness in repelling a infection and disease is a headache for experts because it makes it difficult to achieve herd immunity.

The US virologist Angela Rasmussen – vaccinated herself with Johnson & Johnson – reports on her Twitter account that she is in favor of a second vaccination With Biontech as a booster. She recommends keeping an eye on the so-called breakthrough infections in the Janssen vaccine. Post-vaccination infections have been reported in South Africa.

Since the end of May, the J&Jvaccine in Germany also given to general practitioners’ practices. But experts do not think the single vaccination is a good idea.

Dr. In an interview with t-online, Ulf Dittmer, Director of the Institute for Virology at the Essen University Hospital, demands that Johnson & Johnson not be used: “With regard to vaccines, the mRNA vaccines remain the benchmark. For example, I consider it irresponsible to use Johnson & Johnson. -Johnson vaccine to be given in the company and family doctor’s practices. Only one vaccination is necessary here, but the protective effect against infection is correspondingly reduced. “

According to the company, the vaccine shows a high level of effectiveness against the Delta variant of the Coronavirus. As the manufacturer announced, the vaccine reduced a severe course to 85 percent. This is significantly less than when the vaccine was approved before the delta mutant became rampant.

The crux of the matter is single vaccination

Dr. Stephan Borte, immunologist at the St. Georg Clinic in Leipzig, has concerns about the protective effect of the vaccine: “With a single vaccination like the one at Johnson & Johnson, it is doubtful that sufficient, lasting protection is built up from antibodies and defense cells,” he explains in an interview with t-online. “I would be surprised if permanent protection was actually built up after this single vaccination.”


The sticking point remains the single vaccination. Borte explains: “That immune system reacts to intruders either with a toleration or with a specific immune response in order to render dangerous intruders harmless. This requires repetition, i.e. multiple confrontations with the opponent. Without a memory of the intruder, the immune system develops little or no protective antibodies because it rules out a new confrontation. “

Effectiveness of J&J vaccine could be increased

The Johnson & Johnson vaccine could become more effective in two ways:

A refresher: To do this, a second dose would have to be inoculated, especially under the premise that the Virus mutated and Delta might not have been his last variant.

A cross vaccination: The virologist Rasmussen showed the way. After the vector vaccine Johnson & Johnson, an mRNA vaccine could be used as a booster, which additionally stimulates the immune system. Experts speak of a heterologous vaccination schedule when combining two vaccines.

Dr. Andreas Radbruch, Immunologist and Scientific Director of the German Rheumatism Research Center in Berlin, believes that reinforcing the protective effect through a second vaccination with Biontech is right: “That makes a lot of sense, because J&J is approved as a single vaccine, but it is rather weak Primarily marketing reasons. With Biontech, the effect is predictably and drastically increased, and with the slightly different way in which the virus protein is encoded by Biontech, the vaccination protection should also be broader. “

Cross vaccination also recommended at Astrazeneca

Combination vaccinations have also been shown to be very effective with the other vector vaccine (Astrazeneca). Against the background of the delta variant, which is also rapidly spreading in Germany, the Standing Vaccination Commission changed theirs Vaccination recommendation for the vaccine.

For example, people who have received a first dose of Astrazeneca should in future have an mRNA vaccine such as Biontech or as a second injection, regardless of age Modern received, announced the committee. The interval between the first and second dose should then be at least four weeks. The recommendation applies “subject to the feedback from the comment procedure, which has yet to be opened,” it said.

The experts justify this advice by stating that the immune response after the administration of two different preparations – first vector, then mRNA vaccine – is “clearly superior” to the immune response after two doses of Astrazeneca.

Important NOTE: The information is in no way a substitute for professional advice or treatment by trained and recognized doctors. The contents of t-online cannot and must not be used to independently make diagnoses or start treatments.

.

Coronavirus: After the DNU, the signing of the contract for Moderna or Johnson & Johnson vaccines has already been signed | Negotiations with Pfizer also advance

If everything goes normally, On Tuesday, the first contract will be signed with a North American laboratory for the supply of vaccines: it will be with Johnson & Johnson or Moderna, the two that have already given the ok. The agreement with Pfizer is also ending, but it will not be reached on Tuesday. “The needs of the laboratories were preserved and at the same time we supported the interests of the State,” said Health Minister Carla Vizzotti on Saturday about the DNU and the agreements. In parallel, Also on Tuesday, a donation agreement will be signed from the United States government to the Argentine government of 2,500,000 doses of vaccines produced by the three North American laboratories.. This agreement could not be signed without the agreement with the laboratories because guarantees and insurance were required. The donation agreement is supposed to be signed by a State Department official and the Argentine ambassador in Washington, Jorge Argüello. In parallel, there are rumors in the North American capital that Joe Biden would announce new donations.

Monday is a holiday in the United States and for that reason he stayed on Tuesday to finalize the signatures. The Casa Rosada maintains confidentiality regarding the laboratory with which the first contract is signed. However, Pfizer sources revealed that his contract is still a few days away, so on Tuesday the agreement will be with Johnson & Johnson or Moderna.

In both cases, the authorization of the Anmat is still pending. The version is that the Argentine comptroller body would give the go-ahead in a few days, something that had been rumored. It is important in both cases for several reasons:

* Moderna is moving towards authorization to apply to minors.

* Johnson & Johnson is a single dose and would solve the problem for many people reluctant to sign up and get vaccinated.

* The two vaccines are candidates for a combination with those already applied in Argentina.

Of equal or greater importance is the signing of the agreement with the government of Washington. The quantities for the first shipment are clear: 2.5 million doses of vaccines from Pfizer, Moderna and Johnson & Johnson. In the United States they say they could still send them in July, but it will depend on the speed with which the contracts are signed and the vaccines are approved by Anmat.

In Washington there are strong rumors that Biden would announce new donations. It is not an attack of new humanitarianism, but rather the conviction in the United States government that it is essential to vaccinate the entire world to avoid new variants and, above all, that the virus affects the North American economy again.

The DNU signed by Alberto Fernández on Friday night was the product of long months of negotiations, especially in terms that have to do with the responsibilities in cases of death or damage to health and also in a timely manner with regard to the guarantees in in case compensation has to be paid. The text was discussed in extensive meetings by Zoom in which were the Minister Vizzotti, the presidential advisor Cecilia Nicolini, the Secretary of Legal and Technical, Vilma Ibarra, representatives of the laboratories and officials of the State Department. Therefore, once the DNU is published, contracts and agreements are expected to flow more or less quickly.

Argentina received and will receive in July an enormous quantity of vaccines – surely more than 15 million doses – so that these agreements carry more political weight than in the field of health. It is to normalize things with Washington without impeding a donation and to end one of the many controversies with the opposition. At the same time, the range of vaccines is opening, so that Argentina will have all those that are offered internationally today

.

Moderna and Biontech have been protecting against Corona for years

Is a booster vaccination necessary for the vaccines from Moderna and Biontech? A new study shows that immunization from the vaccines could last a long time.

How long do Biontech / Pfizer and Moderna vaccines protect against the coronavirus? According to a scientific study from “Nature” magazine, the vaccines are said to trigger an immune response in the body that lasts for years. That would mean that most people who have been immunized by the vaccines may not need a booster unless new variants develop. However, the scientists cannot yet guarantee that.

“It’s a good sign of how durable our immunity is after this vaccine,” study leader Ali Ellebedy, immunologist at Washington University in St. Louis, told the New York Times about the results. The vaccine from Johnson & Johnson was not taken into account in the study, but he assumes that the immune response is less permanent than that of the mRNA vaccines.

According to the study, the researchers believe that people who have been infected and later vaccinated will potentially produce immune cells against the coronavirus for life. However, it is unclear whether vaccination alone could have a similar long-lasting effect.

.

Johnson & Johnson is getting out of the opioid business

Dhe US pharmaceutical company Johnson & Johnson no longer wants to manufacture and sell opioid pain relievers in the US. As New York attorney general Letitia James announced on Saturday, the drug manufacturer committed itself in a multi-million dollar settlement with the state of New York to “get out of the opioid business nationwide”. Johnson & Johnson also agreed to a compensation payment of 230 million dollars (192.6 million euros), which can be stretched over nine years.

According to the attorney general’s office, the money will be invested in prevention and education projects as well as in the treatment of opioid addicts in New York State. Should the state create a compensation fund in the first year, it would be said to be another $ 30 million due.

Millions of people dependent

The opioid crisis has “wreaked havoc in numerous locations in New York and across the country,” said Attorney General James. Millions of people are still dependent on the “dangerous and deadly” pain killers. Johnson & Johnson participated in “igniting this fire”. Now the company has committed itself to get out of business – “not just in New York, but across the country.”

In the USA, several large pharmaceutical companies are faced with billions in compensation claims because of the opioid crisis. The opioids include the pain reliever fentanyl, which is 50 times stronger than the illegal opioid drug heroin and is highly addictive. Fentanyl was originally used to treat severe pain, particularly in cancer patients, but doctors have also increasingly prescribed it to other patients.

.

Delta variant: Do Johnson & Johnson, Biontech, Moderna, Astrazeneca protect?

pandemic

This is how Biontech, Moderna and Co. protect against Delta variants

Delta variant: how at risk are children?

Delta variant: how at risk are children?

The Delta variant is preparing Germany for concern. Above all, the higher risk of infection and the lack of vaccination protection after just one dose alarmed experts: Children in particular are at risk.

show description

How effective is the vaccine against the Delta variant? Do Johnson & Johnson, Biontech, Astrazeneca and Moderna protect?

Berlin.

  • The delta version is causing uncertainty in Europe: Although the corona incidences are falling in many countries, the highly contagious delta version is spreading more and more
  • The question that many ask: Will the vaccinations against the mutation first discovered in India help?
  • How effective are Astrazeneca, Moderna, Johnson & Johnson and Biontech? You can find an overview here

The prospects for the summer actually seem rosy: The number of people in Germany who have received at least one first corona vaccination against the corona virus is increasing sharply, while new infections are falling steadily. The nationwide seven-day incidence fell rapidly in the last five weeks not only below 100, but even below 10 cases per 100,000 inhabitants in one week. Read about it: This is Christian Drosten’s fear of the spread of the delta in Germany.

But the corona pandemic is probably far from over. Concern about the possibly more dangerous Delta variant of the virus, which is also spreading in this country, is increasing. While the corona cases are decreasing overall, a constant number of people are still infected with the new mutant. Experts fear that it could have prevailed as the dominant variant of the coronavirus against the alpha variant (B.1.1.7) by autumn.

According to the latest data from the Robert Koch Institute (RKI), the variant has already been detected in all 16 federal states. In the 22nd calendar week, their share of all corona infections examined in more detail in Germany was 6.2 percent. The situation is completely different in Great Britain, where variant B.1.617.2 is now responsible for 96 percent of all new infections.





Delta variant could become a danger in autumn

If a similar development occurs in Germany, it could not only have far-reaching consequences for the unvaccinated part of the population – especially children and adolescents. The spread of the Delta variant could also pose a health risk for vaccinated and convalescent people, as it is apparently more resistant to vaccines than other variants.

So how do the individual vaccines work when infected with the Delta variant? Initial studies are now providing an insight into this. These are the results at a glance. Also read: Delta variant: why the rapid tests do not recognize it

How effective is Biontech’s corona vaccine against the Delta variant?

At the beginning of June, a British study was published in the journal “The Lancet”, which examined in the laboratory how well antibodies against the different variants of the coronavirus can form after vaccination with the different vaccines.

The researchers were able to prove that the number of antibodies after two doses of the Biontech preparation was six times lower in the Delta variant than in the wild-type virus.

The so-called Antibody titer only weakened by a factor of 2.6 and compared to the beta variant identified for the first time in South Africa by a factor of 4.9.

However, while the number of antibodies is an important characteristic of a vaccine’s effectiveness, it is not the only one. Attention must also be paid to the extent to which this immune system attacks already infected cells – but this cannot necessarily be found out in the laboratory.


Biontech almost completely prevents severe Covid-19 courses

Initial studies on this under real conditions give hope: according to a recent study by the British health authority Public Health England (PHE), a complete Biontech vaccination can prevent severe disease progression with the Delta variant as effectively as with the Alpha variant. Two doses of the active ingredient prevented one in variant B.1.617.2 in 96 percent of the cases inpatient treatment.

A study published by the British health authorities at the end of May also provided similar findings for less severe forms of the disease. According to this, the Biontech vaccine is 88 percent effective against a symptomatic Covid 19 disease triggered by the Delta variant two weeks after the second dose.

The protection is significantly lower if you are only simply vaccinated. The study published in “The Lancet” showed that 79 percent of those vaccinated had “a quantifiable neutralizing antibody reaction” against the original virus strain after a first dose of Pfizer / Biontech, compared with only 32 percent for variant B.1.617.2.

Also Biontech boss Hawk assumes effectiveness at Delta

Since two vaccinations are effective against the delta variant, the company is not planning to update the vaccine for the time being. Biontech boss Ugur Sahin explained on Tuesday at the company’s online general meeting: “There is currently no evidence that our vaccine needs to be adapted to the variants in circulation.”


However, he emphasized that it is precisely because of the mutants that the debate about re-vaccinations is gaining in importance: “I assume that a third vaccination could be of great value for boosting immunity. However, we do not yet know when and how often one Booster vaccination will be required ”, so Hawk.


Delta variant: This is how the Astrazeneca corona vaccine works

PHE researchers found in the same study that the Astrazeneca vaccine was a 60 percent effectiveness against the Delta variant and a 66 percent against the Alpha variant. Provided that the person who comes into contact with the mutant is fully immunized.

Severe course of the disease prevents vaccination with the preparation of the British-Swedish pharmaceutical company with a rate of 92 percent. This means that completely vaccinated people are very likely to be protected from conditions that require hospitalization or the like, even if they are infected with the delta variant.

Scientists agree that even with the Astrazeneca vaccine, a single dose offers only limited protection against infection by the Delta variant. The French Pasteur Institute also stated one single astrazeneca dose have “little to no effectiveness” against the Delta variant.

British government data shows that three weeks after the first dose, the immune protection was only 33 percent effective against symptomatic Covid-19 disease caused by the Delta variant.

Moderna and Johnson & Johnson have yet to provide data

Basically, the British health authorities found in investigations of the vaccine’s effectiveness that all vaccines relatively reliably prevent symptomatic Covid-19 diseases in the case of a delta infection after complete immunization and almost completely prevent hospitalizations. However, the perception of the second vaccination is significant – without the risk of symptomatic or even severe disease progression is significantly higher.

The effectiveness of the Moderna and Johnson & Johnson vaccines with respect to the novel mutant has yet to be investigated. The top medical advisor to US President Joe Biden, Anthony Fauci, was optimistic in a recent interview with the Washington Post. Just the preparation from Moderna, the one on the same mRNA-Technologie structured like the Biontech vaccine, should offer a similar protection, explained the immunologist.




(with dpa)


.

J&J does not keep quantities: Contract overfulfilled: Biontech drives back

J&J does not keep quantities
Contract overfulfilled: Biontech drives back

In order for the German vaccination campaign to move forward quickly, Biontech is delivering more than agreed in June and is reducing the quantities in July. Moderna also provides figures for its vaccine. The EU reports failures for Johnson & Johnson, but does not see its goal in jeopardy.

As planned, fewer doses from the most important manufacturer Biontech are expected for the corona vaccinations in Germany in July than in June. With an early delivery, Biontech has made it possible for significantly more cans to be delivered in the second quarter and especially in June than originally assumed, said the Federal Ministry of Health. It was always clear that the total delivery volume would drop to 40.2 million cans in the third quarter.

Around 50 million cans are expected in the second quarter, which will run until the end of June. For July, the company has so far only had concrete forecasts for the first week. After the total amount, however, an average of around 3.3 million doses per week can be calculated. The ministry explained that these figures were also transparently communicated to the federal states. According to a new overview published, a good 3.2 million doses from Biontech are expected in the week starting July 5. In the current week there are therefore 4.6 million doses. In the weeks of June 21st and June 28th, 5.7 million cans are expected to arrive.

Moderna increases the weekly average

Biontech said they had over-fulfilled the contract for the second quarter. “We will deliver more doses in June than originally agreed in order to support and accelerate the vaccination campaigns in Europe and thus also in Germany,” said a company spokeswoman. In the third quarter and thus also in July, the number of cans will be delivered as contractually agreed.

According to the delivery overview, there are also specific figures for the preparation from Moderna for July. 733,200 cans are expected per week, slightly more than the weekly average in June. According to the EU Commission, the manufacturer Johnson & Johnson cannot meet its delivery target for corona vaccines by the end of June. The amount of 55 million cans promised to the EU countries in the second quarter will not be reached, said a Commission spokesman in Brussels. He cannot yet say how much will be delivered. However, the spokesman reiterated the goal of having enough corona vaccine from various manufacturers by the end of July so that 70 percent of adults in the EU can be vaccinated.

.

Department of Health expects quick deliveries from Johnson & Johnson


The Johnson & Johnson vaccine.
Image: AFP

In July, the Federal Ministry of Health asked Johnson & Johnson to deliver missing corona vaccination doses. The US vaccine maker will deliver 6.5 million doses fewer than planned due to a production breakdown by the end of June.

Dhe Federal Ministry of Health is demanding that the vaccine manufacturer Johnson & Johnson deliver missing corona vaccine doses in July. According to the latest information, Johnson & Johnson will deliver around 6.5 million doses less than planned in the second quarter – i.e. by the end of June – according to a ministry spokeswoman. “That is unfortunate, because every vaccine box counts. We therefore expect Johnson & Johnson to deliver this amount as soon as possible in July. ”Several media had previously reported.

The US drug authority FDA had previously discovered numerous deficiencies when inspecting a production facility of the US group and only partially approved the vaccine produced there. Several loads are no longer usable due to possible contamination, among other things, other loads are still being investigated, the FDA announced on Friday. US media reported that around 10 million doses of vaccine had been released and around 60 million needed to be disposed of. The FDA said on Friday that the factory has not yet been released.

Regarding the delivery quantities of the three other vaccines approved in the EU, the Ministry of Health said: “As of today, we are expecting Biontech with 50.3 million doses, Moderna with 6.4 million doses and AstraZeneca with 12.4 million doses each meet current delivery commitments for the second quarter. “

.